Project Grant K23HL175128
Award Date 9/25/25
Completion Date 7/31/30
Dollars Obligated $165K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $700,857 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on "Imaging the Respiratory Effects of Truncal Adiposity in Acute Hypoxemic Respiratory Failure." The project aims to use computed tomography (CT) imaging to investigate how the magnitude and distribution of truncal adiposity (excess fat...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...
- The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $712,268 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the Uganda Lung Health Study. This 5-year longitudinal study aims to investigate the intersection of HIV, sex, and chronic obstructive pulmonary disease (COPD) risk among 800 adolescents and adults in Sub-Saharan Africa, a region expected to...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $170,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of the airway hillock cell type in airway barrier function and regeneration. The award period runs from September 15, 2025 to August 31, 2030. The research aims to define the mechanisms by which the hillock cell resists injury and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $170,640 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on August 15, 2025. The grant supports research by Dr. Tristan Kooistra, a physician-scientist at MGH and Harvard Medical School, to investigate how epithelial-derived Notch signals promote the maturation of airway macrophages and influence allergic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...